VolitionRx (NYSE:VNRX) Stock Price Down 8.5% – Should You Sell?

VolitionRx Limited (NYSE:VNRX)’s share price was down 8.5% during mid-day trading on Wednesday . The company traded as low as $0.2203 and last traded at $0.2241. Approximately 2,703,295 shares changed hands during trading, an increase of 10% from the average daily volume of 2,460,498 shares. The stock had previously closed at $0.2450.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on VNRX shares. HC Wainwright cut their price target on VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Monday, November 17th. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 target price on shares of VolitionRx in a research note on Wednesday, January 21st. Finally, Maxim Group lowered VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, VolitionRx presently has a consensus rating of “Buy” and an average target price of $2.50.

VolitionRx Price Performance

The stock has a market cap of $29.36 million, a P/E ratio of -0.62 and a beta of 1.29. The company has a fifty day moving average of $0.28 and a 200 day moving average of $0.45.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Lagoda Investment Management L.P. raised its position in VolitionRx by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock worth $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Armistice Capital LLC grew its stake in shares of VolitionRx by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of VolitionRx by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the company’s stock worth $246,000 after purchasing an additional 85,816 shares in the last quarter. Citadel Advisors LLC lifted its stake in VolitionRx by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC boosted its holdings in VolitionRx by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after buying an additional 31,300 shares in the last quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.